arrow
曹磊 封面图

曹磊 (Lei Cao)

soochow university - china副教授
H指数:12
被引数:624

个人简介

"曹磊 作者:基础医学院 日期:2022-12-01 点击:3362 曹磊,副教授,博士,硕士生导师科学研究方向帕金森病的病理机制研究与药物靶点发现联系方式通讯:江苏省南京市江宁区龙眠大道101号药理学系,邮编211166电话:025-86869339电邮:leicao@njmu.edu.cn简介南京医科大学2022年引进人才,主要从事神经系统疾病包括帕金森病、脑卒中和阿尔茨海默症的病理机制研究,发现与确证潜在的药物治疗靶点。近年来以第一作者身份在Science Advances, Pharmacology & Therapeutics, Brain Behavior and Immunity, Cell Death & Disease期刊发表论文。担任CNS Neuroscience & Therapeutics、《药物评价研究》杂志的审稿专家。承担科研课题 1.国家自然科学基金青年基金项目,JWA调控铁死亡治疗帕金森病的机制研究及其小分子药物的药效评估,82204357,30万,2023.01-2025.12,主持;代表性论文1. Cao, L., Xiong, S., Wu, Z., Ding, L., Zhou, Y., Sun, H., Zhu, M., Lee, W. T., Nie, X., & Bian, J. S. (2021). Anti-Na(+)/K(+)-ATPase immunotherapy ameliorates alpha-synuclein pathology through activation of Na(+)/K(+)-ATPase alpha1-dependent autophagy. Sci Adv, 7(5). https://doi.org/10.1126/sciadv.abc50622. Cao, L., Cao, X., Zhou, Y., Nagpure, B. V., Wu, Z. Y., Hu, L. F., Yang, Y., Sethi, G., Moore, P. K., & Bian, J. S. (2018). Hydrogen sulfide inhibits ATP-induced neuroinflammation and Abeta(1-42) synthesis by suppressing the activation of STAT3 and cathepsin S. Brain Behav Immun, 73, 603-614. https://doi.org/10.1016/j.bbi.2018.07.0053. #Cao, X., #Cao, L., Zhang, W., Lu, R., Bian, J. S., & Nie, X. (2020). Therapeutic potential of sulfur-containing natural products in inflammatory diseases. Pharmacol Ther, 216, 107687. https://doi.org/10.1016/j.pharmthera.2020.1076874. #Shi, M., #Cao, L., Cao, X., Zhu, M., Zhang, X., Wu, Z., Xiong, S., Xie, Z., Yang, Y., Chen, J., Wong, P. T. H., & Bian, J. S. (2018). DR-region of Na(+)/K(+) ATPase is a target to treat excitotoxicity and stroke. Cell Death Dis, 10(1), 6. https://doi.org/10.1038/s41419-018-1230-55. #Liu, Y., #Cao, L., Song, Y., Kang, Z., Liu, T., Ding, J., Hu, G., & Lu, M. (2022). Mitochondrial glutamine transporter SLC1A5_var, a potential target to suppress astrocyte reactivity in Parkinson's Disease. Cell Death Dis, 13(11), 946. https://doi.org/10.1038/s41419-022-05399-z"

教育背景

暂无内容

工作经历

  • 2022.01 – 至今

    南京医科大学

    副教授

荣誉奖项

暂无内容

Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial

3%普美替尼凝胶治疗轻至中度特应性皮炎的疗效与安全性:一项多中心、随机、双盲、平行、安慰剂对照的IIb期临床试验

2025-10-010
PRE